| ★ |  GDF2026 - Closing Remarks | U.S. Food and Drug Administration @us_fda | 595 | Estados Unidos | |
| 2 |  GDF2026 - Manufacturing Deficiencies in Liquid Drug Products: The Top Ten Issues | U.S. Food and Drug Administration @us_fda | 602 | Estados Unidos | 94 |
| 18 |  GDF2026 - Updates on Nitrosamines/ Nitrosamine Mitigation Strategies for Pharmaceuticals | U.S. Food and Drug Administration @us_fda | 409 | Estados Unidos | 87 |
| 15 |  GDF2026 - Common Microbiology Deficiencies for Ophthalmic Suspension Drug Products | U.S. Food and Drug Administration @us_fda | 353 | Estados Unidos | 89 |
| 1 |  GDF2026 - ICH M13A High-Risk vs. Low-Risk Case Studies – Bioequivalence (BE) Implications | U.S. Food and Drug Administration @us_fda | 251 | Estados Unidos | 95 |
| 3 |  GDF2026 - Data Integrity in ANDA Applications | U.S. Food and Drug Administration @us_fda | 189 | Estados Unidos | 92 |
| 19 |  GDF2026 - Overview of the FDA Product-Specific Guidance (PSG) Program | U.S. Food and Drug Administration @us_fda | 166 | Estados Unidos | 87 |
| 20 |  GDF2026 - Bioequivalence (BE) Recommendations for Bridging Pre- and Post-Mitigation Formulations | U.S. Food and Drug Administration @us_fda | 160 | Estados Unidos | 86 |
| 7 |  GDF2026 - Best Practices for Safety Assessment of Nitrosamines in Generic Drugs | U.S. Food and Drug Administration @us_fda | 127 | Estados Unidos | 92 |
| 6 |  GDF2026 - Office of Pharmaceutical Quality (OPQ) Keynote | U.S. Food and Drug Administration @us_fda | 101 | Estados Unidos | 92 |
| 12 |  GDF2026 - Pre-Abbreviated New Drug Application (ANDA) Meetings for Complex Drug Products | U.S. Food and Drug Administration @us_fda | 101 | Estados Unidos | 90 |
| 5 |  GDF2026 - Addressing Patent and Exclusivity Requirements – Regulatory Reminders | U.S. Food and Drug Administration @us_fda | 66 | Estados Unidos | 92 |
| 10 |  GDF2026 - Drug-Device Combination Products: A Quality Perspective | U.S. Food and Drug Administration @us_fda | 64 | Estados Unidos | 91 |
| 9 |  GDF2026 - Product-Specific Guidances (PSGs) in Action – Key Lessons and Common Questions | U.S. Food and Drug Administration @us_fda | 58 | Estados Unidos | 91 |
| 14 |  GDF2026 - Standardized Principles Used to Determine Maximum Daily Dose | U.S. Food and Drug Administration @us_fda | 57 | Estados Unidos | 90 |
| 16 |  GDF2026 - Prioritization Requests: Prioritizing Original and Supplemental ANDAs | U.S. Food and Drug Administration @us_fda | 49 | Estados Unidos | 88 |
| 17 |  GDF2026 - Decoding PSGs for Complex Non-Oral Generics | U.S. Food and Drug Administration @us_fda | 49 | Estados Unidos | 88 |
| 4 |  GDF2026 - Using FDA’s Inactive Ingredient Database (IID): Best Practices and Considerations | U.S. Food and Drug Administration @us_fda | 47 | Estados Unidos | 92 |
| 11 |  GDF2026 - Factors that Can Facilitate Assessment of Type II Drug Master Files (DMFs) | U.S. Food and Drug Administration @us_fda | 43 | Estados Unidos | 90 |
| 13 |  GDF2026 - Suitability Petitions | U.S. Food and Drug Administration @us_fda | 41 | Estados Unidos | 90 |
| 8 |  GDF2026 - Controlled Correspondences: Minimizing Rejections, Maximizing Results | U.S. Food and Drug Administration @us_fda | 37 | Estados Unidos | 91 |